Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Brain Behav Immun. 2021 Jan 7;93:80–95. doi: 10.1016/j.bbi.2020.12.016

Figure 1. Repeated systemic administration of the TLR2/TLR4 antagonist (+)-Naltrexone [(+)-NTX], beginning 15 days after intradermal myelin oligodendrocyte glycoprotein (MOG), reverses EAE-related pain in male Dark Agouti rats; no effect on motor scores.

Figure 1.

Male Dark Agouti rats were baselined (BL) for motor scores and for low-threshold mechanical withdrawal thresholds via the von Frey test, followed by intra-dermal low-dose (4 µg) myelin oligodendrocyte glycoprotein (MOG). Allodynia and motor scores were assessed thereafter across the timecourse shown. (+)-NTX (6 or 12 mg/kg subcutaneously [SC] 3x/day) vs. saline was initiated on Day 15 post-MOG, continuing through day 30 (see gray rectangle indicating span of drug delivery). Panels A and B: Both doses of (+)-NTX reversed allodynia, relative to saline control, and did so to a comparable degree. Main effect of drug: left paw: F(2,13) =41.11 p<0.0001; right paw: F(2,13) =36.88 p<0.001; posthocs: 6 and 12 mg/kg (+)-NTX each different from saline (p<0.0001) but not different from each other. Panel C: Neither (+)-NTX dose reliably increased motor scores. N=5–6/group.